As part of FutureMeds’ increased commitment to break down oncology trial barriers, our Wroclaw team welcomed the Director of the Lung Cancer Section at the "To Się Leczy" Foundation.
FutureMeds welcomed the Director of the Lung Cancer Section at the "To Się Leczy" Foundation, Aleksandra Wilk, at the Wroclaw headquartes on 3rd March to discuss the critical importance of raising awareness about clinical trials for oncology patients.
Community based patient engagement
Despite the widespread willingness, only a small fraction of patients with cancer participated in clinical trials. It has been estimated that overall trial participation has stagnated between 2–8% for decades.
FutureMeds believes there is a missing link — a patient-centric, dedicated, and ambulatory-focused approach that can effectively integrate decentralized trial (DCT) elements to break the structural, physician, and patient barriers that currently limit oncology research.
As a complementary solution to the traditional hospital-based approach, our solution aims to help to
Close the efficacy-effectiveness gap (patient populations included in clinical trials are mostly not representative of the majority of patients treated in routine care)
Increase access and patient convenience and provide a sense of “normalcy”
Provide a platform for broader decentralised element adoption in oncology trials
"At FutureMeds, our commitment goes beyond delivering clinical trials for new treatments, we're creating pathways of possibility for patients when they need hope most. By streamlining access to innovative therapies and building a patient-first approach, we're transforming how the clinical research industry support individuals facing their most challenging moments."
— Wojciech Szczepanik PhD, Executive VP of Site Operations
Bridging Information Gaps Within the Communities
Cancer remains a pressing global health issue, with advancements in treatment largely driven by robust clinical research. Yet despite the significance of oncology trials, the broader patient population seldom participates.
“Many of the patients who could benefit most from therapies are never even presented with the chance to join a clinical trial. They are not aware. Our goal is to foster community-wide collaborations and run awareness campaigns that illuminate these potentially life-changing options.”
— Arkadiusz Kasperski, Head of Patient Engagement at FutureMeds Poland
For patients, missed opportunities for new treatments can mean fewer options at critical junctures. For clinical researchers and sponsors, under-enrollment slows progress, delaying regulatory approvals and limiting the real-world applicability of new treatments.
To take a step towards a better future, the meeting between Aleksandra Wilk and FutureMeds focused on three critical aspects of cancer patient care:
The evolving landscape of oncology treatment
The pivotal role of clinical trials in developing innovative therapies
Current challenges facing cancer patients in accessing cutting-edge treatments
A Mission of Hope
We hope that the discussions like these will soon translate into increased access to information about clinical trials, and growing patient awareness.
Cancer diagnosis remains a devastating moment for patients and their families. While registered drug therapies continue to advance, clinical trials often represent the most promising avenue for many patients seeking hope and potential recovery.
"Our mission is to simplify and expedite access to innovative treatments," said Kasperski.
To help drive progress in oncology research, FutureMeds has developed a comprehensive community based patient engagement approach using its dedicated research sites to help break down structural barriers.
Looking Forward
The collaboration between clinical research sites, pharmaceutical sponsors, researchers, patient advocacy groups and patients remains the cornerstone of discovering groundbreaking cancer therapies.
With a diverse and dedicated team, FutureMeds is expanding its expertise in oncology clinical trials. The company plans to broaden its research into solid tumors, melanoma, and hematooncology, demonstrating a commitment to pushing the boundaries of cancer treatment.
Follow us on LinkedIn
Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.
留言